Search

Research

With immune checkpoint therapy (ICT) having reshaped the treatment of many cancers, the next frontier is to identify and develop novel combination therapies to improve efficacy. Previously, we and others identified beneficial immunological effects of the vitamin A derivative tretinoin on anti-tumour immunity.

News & Events

The Kids Research Institute Australia’s cancer researchers will use funds raised in the name of a brave three-year-old girl to launch a new assault on the devastating form of childhood cancer which took her life.

Research

Antibodies that target immune checkpoints such as cytotoxic T lymphocyte antigen 4 (CTLA‐4) and the programmed cell death protein 1/ligand 1 (PD-1/PD-L1) are now a treatment option for multiple cancer types. However, as a monotherapy, objective responses only occur in a minority of patients. Chemotherapy is widely used in combination with immune checkpoint blockade (ICB). Although a variety of isolated immunostimulatory effects have been reported for several classes of chemotherapeutics, it is unclear which chemotherapeutics provide the most benefit when combined with ICB.

News & Events

Researchers from The Kids Research Institute Australia will share in almost $4 million in grants to continue groundbreaking research to tackle childhood cancer, asthma, respiratory viral infections and more.

News & Events

In the field of cancer research, lobbying efforts by the The Kids Cancer Centre have contributed to major initiatives including Australia’s first personalised medicine program for children with high-risk cancer, and a mission to boost survival rates in brain cancer patients.

News & Events

A team of world-leading scientists has secured $5 million in funding from the Leukaemia and Lymphoma Society to advance the fight against leukaemia in children with Down syndrome.

News & Events

Researchers at The Kids Research Institute Australia and UWA will use a $500,000 CUREator grant to progress the development of the first cancer immunotherapy in a tablet.

Research

Platinum-based chemotherapy in combination with anti-PD-L1 antibodies has shown promising results in mesothelioma. However, the immunological mechanisms underlying its efficacy are not well understood and there are no predictive biomarkers to guide treatment decisions.

Research

Event-free survival considers other adverse events in addition to mortality. It therefore provides a more complete understanding of the effectiveness and consequences of treatment than standard survival measures, but is rarely reported at the population level for childhood cancer.

Research

Siblings of children with cancer have been shown to experience disruption in multiple domains including family, school, and friendships. Existing literature on siblings' experiences focuses on older children or on a broad range of ages.